Sangui Biotech International Inc. reported sales results for the year 2016. For the year, the company reported sales of USD 48,000 compared to USD 127,000 a year ago. This decline was attributable to a decrease in license revenues due to lower turnover of the wound treatment product Granulox.

For the first quarter of 2017, for the company expects revenues from royalty income of approximately USD 10 during the first quarter of fiscal year 2017.